Restorbio Inc (NASDAQ:TORC) Short Interest Strengthened By 16.98%

June 27, 2018 - By Joshua Cleveland

It was showed an increase on Restorbio Inc (NASDAQ:TORC)’s short interest with 16.98%. In June was issued TORC’s total 919,600 short interest by FINRA. The 786,100 previous shares are up with 16.98%. 9 days will cost TORC with 107,900 average volume to recover its former position.

TORC hit $9.33 during the last trading session after $0.29 change.Currently resTORbio, Inc. is after 0.00% change in last June 27, 2017. TORC has also 83,701 shares volume. TORC underperformed the S&P500 by 12.57%.

resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases.The firm is worth $261.67 million. The Company’s lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems.Last it reported negative earnings. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system.

There’s a substantial resTORbio, Inc. (NASDAQ:TORC) news published by Nasdaq.com. It’s an item titled: “resTORbio Announces Appointment of Kerry Russell, MD, Ph.D., as Vice President of Clinical Development” on June 12, 2018.

resTORbio, Inc. (NASDAQ:TORC) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.